The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer

SIMPLE SUMMARY: The BET bromodomain inhibitor JQ1 slows tumor growth in preclinical models of pancreatic cancer. However, as a single agent, it does not induce tumor regressions. We hypothesized that JQ1 would sensitize pancreatic tumors to gemcitabine, a drug used for patients with this tumor type....

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Aubrey L., Garcia, Patrick L., Fehling, Samuel C., Gamblin, Tracy L., Vance, Rebecca B., Council, Leona N., Chen, Dongquan, Yang, Eddy S., van Waardenburg, Robert C. A. M., Yoon, Karina J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303731/
https://www.ncbi.nlm.nih.gov/pubmed/34298684
http://dx.doi.org/10.3390/cancers13143470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303731/
https://www.ncbi.nlm.nih.gov/pubmed/34298684
http://dx.doi.org/10.3390/cancers13143470

Ejemplares similares